JCRB1650 RM-P1
Cell information
Important Notice(s)Cell type：virus production cells (View Pricing Information)
| JCRB No. | JCRB1650 | Cell Name | RM-P1 |
|---|---|---|---|
| Profile | Human herpesvirus-8 (HHV-8) and Epstein-Barr virus (EBV) infected B cell line established from pericardial lymphomatous effusions. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 63-year-old |
| Identity | available | Tissue for Primary Cancer | |
| Case history | diabetes, chronic diabetic renal failure, malignant lymphoma | Metastasis | |
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | lymphocyte-like | Character | human herpesvirus-8 (HHV-8) and Epstein-Barr virus (EBV) infection. |
| Classify | tumor | Established by | Miyagi, J. |
| Registered by | Okada, S. | Regulation for Distribution | |
| Comment | ウイルスDNA検査 HHV8(+) | Year | 2014 |
| Medium | RPMI1640 medium with 20% FBS | Methods for Passages | dilution |
| Cell Number on Passage | Race | ||
| CO2 Conc. | 5% | Tissue Sampling | pericardial lymphomatous effusions |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | + | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | HHV8 (+) | ||||||||
| Reference | |
|---|---|
| Pubmed id:19521981 | Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Takahashi-Makise N,Suzu S,Hiyoshi M,Ohsugi T,Katano H,Umezawa K,Okada S Int J Cancer. 2009 Sep 15;125(6):1464-72 |
| Pubmed id:12215016 | Establishment of a primary effusion lymphoma cell line (RM-P1) and in vivo growth system using SCID mice. Miyagi J,Masuda M,Takasu N,Nagasaki A,Shinjyo T,Uezato H,Kakazu N,Tanaka Y Int J Hematol. 2002 Aug;76(2):165-72 |
| Images |
|---|
      |
LOT Information
| Cell No. | JCRB1650 | Cell Name | RM-P1 |
|---|---|---|---|
| LOT No. | 12012015 | Lot Specification | distribution |
| Medium | RPMI1640 medium(GIBCO) with 20% heat inactivated fetal bovine serum(SIGMA12J396) | Temperature | 37 C |
| Cell Density at Seeding | 0.12-1.43x10^6 cells/ml | Methods for Passages | Dilution |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 3.15x10^6 |
| Viability at cell freezing (%) | 79.1 | Antibiotics Used | free |
| Passage Number | p5* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:9,12 D13S317:9,14 D7S820:10 D16S539:12 VWA:17,18 TH01:9 AM:X TPOX:8,11 CSF1PO:10,11 |
| Adhesion | No | Exoteric Gene | NT |
| Medium for Freezing | BAMBANKER(LYMPHOTEC Inc.,CS-02-001,NIPPON Genetics Co., LTD) | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information |
| Images |
|---|
|
|